Kiltearn Partners LLP lowered its holdings in shares of CVS Health Corp (NYSE:CVS) by 1.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 3,152,795 shares of the pharmacy operator’s stock after selling 43,600 shares during the period. CVS Health comprises 5.7% of Kiltearn Partners LLP’s holdings, making the stock its 4th largest holding. Kiltearn Partners LLP owned about 0.31% of CVS Health worth $248,188,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in CVS. BlackRock Inc. raised its stake in shares of CVS Health by 5.9% during the second quarter. BlackRock Inc. now owns 74,135,102 shares of the pharmacy operator’s stock valued at $4,770,597,000 after acquiring an additional 4,121,620 shares during the last quarter. Charles Schwab Investment Advisory Inc. bought a new position in shares of CVS Health during the second quarter valued at $190,701,000. Boston Partners raised its stake in shares of CVS Health by 41.9% during the second quarter. Boston Partners now owns 9,908,888 shares of the pharmacy operator’s stock valued at $637,637,000 after acquiring an additional 2,924,875 shares during the last quarter. Diamond Hill Capital Management Inc. bought a new position in shares of CVS Health during the third quarter valued at $204,536,000. Finally, Morgan Stanley raised its stake in shares of CVS Health by 28.4% during the second quarter. Morgan Stanley now owns 8,358,263 shares of the pharmacy operator’s stock valued at $537,854,000 after acquiring an additional 1,848,678 shares during the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.
NYSE:CVS opened at $74.09 on Friday. The company has a quick ratio of 1.94, a current ratio of 2.44 and a debt-to-equity ratio of 1.66. The firm has a market capitalization of $78.01 billion, a price-to-earnings ratio of 11.23, a P/E/G ratio of 1.10 and a beta of 0.98. CVS Health Corp has a 12 month low of $60.14 and a 12 month high of $83.88.
CVS Health (NYSE:CVS) last posted its quarterly earnings results on Tuesday, November 6th. The pharmacy operator reported $1.73 EPS for the quarter, topping analysts’ consensus estimates of $1.71 by $0.02. The business had revenue of $47.27 billion during the quarter, compared to analysts’ expectations of $47.22 billion. CVS Health had a net margin of 1.65% and a return on equity of 18.69%. The business’s quarterly revenue was up 2.4% on a year-over-year basis. During the same period last year, the company posted $1.50 earnings per share. As a group, research analysts anticipate that CVS Health Corp will post 7.03 EPS for the current year.
Several equities research analysts have recently weighed in on CVS shares. Bank of America increased their price objective on shares of CVS Health from $86.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, September 17th. ValuEngine cut shares of CVS Health from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 4th. Tigress Financial reiterated a “buy” rating on shares of CVS Health in a research report on Friday, October 26th. Royal Bank of Canada increased their price objective on shares of CVS Health to $101.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 18th. Finally, Wolfe Research started coverage on shares of CVS Health in a research report on Thursday, October 25th. They set a “peer perform” rating for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $90.69.
In other CVS Health news, EVP Troyen A. Brennan sold 14,229 shares of the firm’s stock in a transaction on Wednesday, November 14th. The shares were sold at an average price of $82.00, for a total value of $1,166,778.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO David M. Denton sold 25,159 shares of the firm’s stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $80.13, for a total transaction of $2,015,990.67. Following the completion of the sale, the chief financial officer now owns 403 shares of the company’s stock, valued at $32,292.39. The disclosure for this sale can be found here. Insiders sold 74,233 shares of company stock valued at $5,932,565 over the last 90 days. Corporate insiders own 0.53% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “CVS Health Corp (CVS) Stake Lessened by Kiltearn Partners LLP” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/12/08/cvs-health-corp-cvs-stake-lessened-by-kiltearn-partners-llp.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
See Also: Fundamental Analysis
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.